Enliven Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Enliven Therapeutics

07/05/2024 13:02

* Enliven Therapeutics Inc  ELVN.OQ   ELVN.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Enliven Therapeutics Inc
is
for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $34.00​, above​ its last closing price
of $22.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.54      -0.47     Beat    13
 Sep. 30 2023  -0.48       -0.47      -0.51     Missed  -7.9
 Jun. 30 2023  -0.36       -0.36      -0.41     Missed  -14.2​
 Mar. 31 2023  -0.64       -0.63      -0.80     Missed  -26.3
 ​​                                                     
 Sep. 30 2022  -1.00       -1.00      -0.72     Beat    28​
 Jun. 30 2022  -2.03       -2.05      -1.76     Beat    14.1
 Mar. 31 2022  -2.31       -2.31      -2.24     Beat    3.1
 This summary was machine generated May 7 at 12:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)